Is Mounjaro (tirzepatide) Safe? Data from 30,000 Patients

You've heard about Mounjaro (tirzepatide). Maybe even considered trying it. And somewhere on your decision journey, you encountered words like 'boxed warning,' 'cancer risk,' 'pancreatitis.' Then came Google, forums, and panic instead of answers.

Let's pause. And look at the facts.

Mounjaro (tirzepatide), approved by FDA in 2022 for type 2 diabetes and in 2023 for weight management as Zepbound. EMA granted approval in 2023. During this time, the product has been studied in over 30,000 patients in the SURMOUNT and SURPASS programs. And these data tell a story very different from internet horror stories.

What do FDA and EMA say — and why does it matter?

Regulatory approval isn't a formality. To receive FDA approval, a product undergoes three to four phases of clinical trials. Thousands of participants. Years of observation. Independent data auditing.

Mounjaro completed this path entirely. Manufacturer — Eli Lilly, a company with over 140 years of pharmaceutical experience. This isn't a startup from someone's basement.

Each approval is based on specific studies. For diabetes — the SURPASS program. For weight loss — SURMOUNT. Together, this represents tens of thousands of people under medical supervision.

Read more about the mechanism of action on the Mounjaro page.

Cardiovascular safety: what did the study of 13,299 patients show?

One of the biggest questions with any weight loss therapy is heart impact. History knows examples when weight loss products were recalled precisely due to cardiac complications.

Therefore, Eli Lilly conducted the large-scale SURPASS-CVOT study. This isn't a marketing move. It's an FDA requirement for all new diabetes medications.

If you're interested in a comparison with Ozempic — there's a separate article.

Pancreatitis: how real is the risk?

Pancreatitis — pancreatic inflammation. Sounds scary. And that's exactly why FDA includes warnings about it in the labeling of all GLP-1 agonists. But let's look at the numbers.

In tirzepatide clinical studies, pancreatitis occurred in 0.32-0.39% of cases [2]. This is comparable to placebo — meaning the group that received no active product.

A systematic review of 17 randomized studies involving 14,645 people confirmed: pancreatitis risk with tirzepatide doesn't differ from placebo [5].

No dose showed statistically significant risk increase.

Read more about Mounjaro side effects in a separate guide.

Thyroid gland and boxed warning: what's actually happening?

Here's where the biggest confusion begins. FDA places a 'black box' — boxed warning on Mounjaro about C-cell thyroid tumor risk. This is the most serious warning possible.

But here's the context that usually gets lost.

In two-year rodent studies, tirzepatide did cause thyroid C-cell tumors [3]. This is fact. However, there's an important nuance: rodents have significantly more of these cells and they respond differently to GLP-1 stimulation.

What do human data show? In clinical studies with over 10,000 participants over two years, no increase in thyroid nodules or cancer frequency was found [1].

Moreover, a retrospective cohort study of 283,004 patient pairs showed: tirzepatide users had 65% lower malignant thyroid cancer risk than those who didn't take the product [1].

Gallbladder: why do stones form?

This question doesn't only concern Mounjaro. Any rapid weight loss increases gallstone formation risk. Why? When you lose weight, the liver releases more cholesterol into bile. If the gallbladder doesn't empty frequently enough, this cholesterol can crystallize.

In tirzepatide clinical studies, gallbladder disease occurred in approximately 2.5% of users compared to 1% in the placebo group [4]. This increase is related to rapid weight loss itself, not direct product action.

Gallbladder disease symptoms: right upper abdominal pain after fatty foods. Monitored via ultrasound.

Compared to GLP-1 agonists (like Ozempic), tirzepatide has a similar safety profile. The difference — dual mechanism of action (GLP-1 + GIP), which provides greater efficacy at similar risk levels.

About differences between Mounjaro and Ozempic.

The thyroid gland boxed warning is based on rodent studies. In humans, the link isn't confirmed, and some data even show reduced cancer risk among tirzepatide users [1].

Pancreatitis occurs no more frequently than with placebo [2]. Gallstones are related to rapid weight loss in general, not specifically to the product.

If you have no contraindications — Mounjaro is one of the most studied and safe options for weight management in 2026.

All this data points to one thing: safety issues deserve attention, but not panic. If you want to figure out what's right for you — write to Telegram @Doza_sofia_bot↗. A specialist will respond within an hour.

Where to order Mounjaro in Ukraine

Ready to start the course? Buy Mounjaro in Ukraine is available in the DOZA catalog — all 6 doses (2.5, 5, 7.5, 10, 12.5, 15 mg) with official thermal delivery within 24 hours and 24/7 specialist support. Current Mounjaro prices 2026 — from 1,000 ₴ for a test dose or 8,000 ₴/month for a full program with monitoring.

Where to order DOZA products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Ozempic in Ukraine — original semaglutide from Novo Nordisk with thermal delivery. Current Ozempic prices 2026 — from 1,600 ₴ for a starter dose.